Celltrion acquires Australian approval of trastuzumab biosimilar ‘Herzuma’
Celltrion recently announced they acquired sales approval of therapeutic antibody biosimilar for breast cancer and stomach cancer ‘Herzuma(generic name: trastuzumab)’ from the Australian Therapeutic Goods Administration.
‘Herzuma,’ the only trastuzumab biosimilar which acquired the approval in A...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.